Statins in risk-reduction and treatment of cancer

Area of Science:

• Biochemistry and Pharmacology
• Oncology
• Drug Discovery

Background:

• Statins are primary inhibitors of HMG-CoA reductase, widely used for cholesterol reduction and cardiovascular disease prevention.
• Beyond lipid-lowering, statins exhibit pleiotropic effects, including antioxidant, anti-inflammatory, and antiproliferative activities.
• These properties have spurred research into statins' potential applications in various pathologies, including cancer.

Purpose of the Study:

• To investigate the antiproliferative effects of statins on diverse cancer types.
• To evaluate the efficacy of statins as monotherapy and in combination with cytotoxic drugs for cancer treatment.
• To explore the impact of statin use on cancer risk and patient outcomes through observational studies.

Main Methods:

• In vitro and in vivo studies assessing statin effects on cancer cell lines and animal models.
• Clinical trials examining the efficacy of statins in cancer patients.
• Observational studies analyzing patient data on statin use and cancer incidence/outcomes.

Main Results:

• Statins demonstrated antiproliferative effects against various cancers, with outcomes influenced by statin properties, dose, and duration.
• Combined statin and cytotoxic drug therapies showed synergistic or additive anticancer effects.
• Observational studies indicated that statin use is associated with reduced cancer risk and improved outcomes in cancer patients.

Conclusions:

• Statins possess significant anticancer potential, attributed to their antiproliferative and other pleiotropic effects.
• Further clinical trials are warranted to establish statins as a viable therapeutic strategy in oncology.
• Statin therapy may offer a dual benefit of cardiovascular protection and cancer risk reduction or improved prognosis.